Company Disclosure: Strategic Acquisition and Expansion
Acquisition Details
- Tavexia Lifecare Limited has acquired a 60% controlling equity stake in Meyonex Pharmaceuticals Limited
- Acquisition value: ₹67.19 Crore
- Transaction executed through cash subscription of 2,09,97,180 fresh equity shares
- Issue price: ₹32 per share
- Acquisition provides immediate operational foothold through Meyonex's established manufacturing and commercial operations located in MIDC Tarapur, Maharashtra
Strategic Expansion
The company has altered its Main Object Clause under its Memorandum of Association to expand into several high-growth segments:
- Active Pharmaceutical Ingredients (APIs) & Bulk Drugs
- Finished Dosage Forms & Formulations (tablets, capsules, injectables, and advanced delivery formats)
- CDMO & CRAMS Services (Contract Research and Manufacturing Services and Contract Development and Manufacturing Organizations)
- Nutraceuticals & Biotechnology
Financial and Strategic Outlook
- Management has initiated plans for strategic fund-raising through permissible equity or convertible instruments
- Acquisition expected to deliver significant synergies and provide immediate growth runway
- Company aims to scale revenue baseline and leverage operational efficiencies
- Positioning to benefit from sector tailwinds including domestic manufacturing support, global supply-chain diversification ("China+1" strategies), and demand for specialized generic formulations